U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C7H5O2.Li
Molecular Weight 128.0537
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LITHIUM BENZOATE

SMILES

c1ccc(cc1)C(=O)[O-].[Li+]

InChI

InChIKey=LDJNSLOKTFFLSL-UHFFFAOYSA-M
InChI=1S/C7H6O2.Li/c8-7(9)6-4-2-1-3-5-6;/h1-5H,(H,8,9);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula Li
Molecular Weight 6.94
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C7H5O2
Molecular Weight 121.1137
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment:: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/19538681 | https://www.ncbi.nlm.nih.gov/pubmed/23371914 | http://www.rsc.org/periodic-table/element/3/lithium

Lithium gluconate is used in oligotherapy for psychological problems (normothymia, manic depressive psychosis) under special biological surveillance and more specifically when the lithium rate is to be controlled. Lithium gluconate ointment was significantly more effective than placebo, with a complete clinical remission after 4 and 8 weeks respectively in the treatment of seborrhoeic dermatitis. At low concentration (1.6 mM), Li enhanced TNFalpha secretion, whereas, at higher concentration (5 mM), Li significantly enhanced IL10 expression and secretion in skin models. However, there was no significant modulation of Li on IL6 and TGFbeta1 secretion. Moreover, Li at 5 mM significantly decreased TLR2 and TLR4 expressions by differentiated keratinocytes. As Li concentration during topical treatment is probably closer to 5 mM than to 1 mM, the therapeutic effect of Li gluconate in seborrhoeic dermatitis may be explained by two anti-inflammatory actions: an increased expression and secretion of IL10 and a decreased expression of TLR2 and TLR4 by keratinocytes.

Originator

Curator's Comment:: The first lithium mineral petalite, LiAlSi4O10, was discovered on the Swedish island of Utö by the Brazilian, Jozé Bonifácio de Andralda e Silva in the 1790s. It was observed to give an intense crimson flame when thrown onto a fire. In 1817, Johan August Arfvedson of Stockholm analysed it and deduced it contained a previously unknown metal, which he called lithium. He realised this was a new alkali metal and a lighter version of sodium. However, unlike sodium he was not able to separate it by electrolysis. In 1821 William Brande obtained a tiny amount this way but not enough on which to make measurements. It was not until 1855 that the German chemist Robert Bunsen and the British chemist Augustus Matthiessen obtained it in bulk by the electrolysis of molten lithium chloride.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
6.53 µM [IC50]
2.0 mM [Ki]
Target ID: O95861
Gene ID: 10380.0
Gene Symbol: BPNT1
Target Organism: Homo sapiens (Human)
0.3 mM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LITHIUM CARBONATE

Approved Use

Lithium is indicated in the treatment of manic episodes of Bipolar Disorder.

Launch Date

-1.26316798E11
PubMed

PubMed

TitleDatePubMed
[Lithium therapy in manic depressive diseases in old age].
1975
Renal failure associated with acetazolamide therapy for glaucoma.
1975 Apr
Obsolete but dangerous antacid preparations.
1978 Jan
Organophosphate poisoning: modifications in acid base equilibrium and use of sodium bicarbonate as an aid in the treatment of toxicity in dogs.
1983 Feb
Calcification of superficial scalp veins secondary to intravenous infusion of sodium bicarbonate and calcium chloride.
1983 Jul
[Effect of antacids on mineral metabolism].
1983 Mar
Experimental amitriptyline intoxication: electrophysiologic manifestations and management.
1984 Jan-Feb
Treatment of ventricular tachyarrhythmias resulting from amitriptyline toxicity in dogs.
1984 Nov
Urothelial injury to the rabbit bladder from various alkaline and acidic solutions used to dissolve kidney stones.
1986 Jul
The effect of pH buffering on reducing the pain associated with subcutaneous infiltration of bupivicaine.
1991 Mar
Sodium bicarbonate alleviates penile pain induced by intracavernous injections for erectile dysfunction.
1993 May
Alkalinization of local anesthesia with sodium bicarbonate--preferred method of local anesthesia.
1994 Jan
Effects of magnesium sulfate and lidocaine in the treatment of ventricular arrhythmias in experimental amitriptyline poisoning in the rat.
1994 Mar
Reversal of flecainide-induced ventricular arrhythmia by hypertonic sodium bicarbonate in dogs.
1995 May
Reduction of desipramine cardiotoxicity and prolongation of survival in rats with the use of polyclonal drug-specific antibody Fab fragments.
1995 Sep
Effect of calcium chloride and 4-aminopyridine therapy on desipramine toxicity in rats.
1996
Pathophysiology and treatment of cocaine toxicity: implications for the heart and cardiovascular system.
1996 Dec
Metabolic alkalosis and myoclonus from antacid ingestion.
1996 Jun
Suppression of herpes simplex virus infections with oral lithium carbonate--a possible antiviral activity.
1996 Nov-Dec
Therapy of Sjögren's syndrome. New aspects and future directions.
1998 Feb
Oral sodium bicarbonate reduces proximal renal tubular peptide catabolism, ammoniogenesis, and tubular damage in renal patients.
1998 Mar
The effects of sodium bicarbonate on thioridazine-induced cardiac dysfunction in the isolated perfused rat heart.
2001 Apr
Influence of strain, sex and age on nephrotoxicity of lithium in a one-hour model in rats.
2001 Dec
Ménière's disease in childhood.
2001 Dec 1
Prevention of cannabinoid withdrawal syndrome by lithium: involvement of oxytocinergic neuronal activation.
2001 Dec 15
[A case of atropine-resistant bradycardia in a patient on long-term lithium medication].
2001 Nov
Tetraspan protein CD151: a common target of mood stabilizing drugs?
2001 Nov
Aborted sudden death, transient Brugada pattern, and wide QRS dysrrhythmias after massive cocaine ingestion.
2001 Oct
Mild to severe lithium-induced nephropathy models and urine N-acetyl-beta-D-glucosaminidase in rats.
2001 Oct
Synergistic induction of severe hypothermia (poikilothermia) by limbic seizures, acepromazine and physical restraint: role of noradrenergic alpha-1 receptors.
2001 Oct-Nov
Sinus node dysfunction associated with lithium therapy in a child.
2002
Lithium-induced tremor treated with vitamin B6: a preliminary case series.
2002
Intracerebroventricular antisense to inositol monophosphatase-1 reduces enzyme activity but does not affect Li-sensitive behavior.
2002 Jan
Aminophylline aggravates long-term morphological and cognitive damages in status epilepticus in immature rats.
2002 Mar 22
Lithium induces NF-kappa B activation and interleukin-8 production in human intestinal epithelial cells.
2002 Mar 8
Olanzapine-induced mania in bipolar disorders.
2002 May
[Progressive renal failure caused by lithium nephropathy].
2002 May 25
Risk factors for falls during treatment of late-life depression.
2002 Oct
Sexual side effects associated with valproate.
2002 Oct
Status epilepticus induced by lithium-pilocarpine in the immature rat does not change the long-term susceptibility to seizures.
2002 Sep
Lithium toxicity: a potential interaction with celecoxib.
2002 Sep-Oct
Reverse pharmacological effect of loop diuretics and altered rBSC1 expression in rats with lithium nephropathy.
2003 Jan
Lithium-induced periodic alternating nystagmus.
2003 Jan 28
The prevention of pain from injection of rocuronium by magnesium sulphate, lignocaine, sodium bicarbonate and alfentanil.
2003 Jun
Fanconi syndrome caused by antiepileptic therapy with valproic Acid.
2004 Jul
Comparison of usefulness of sodium bicarbonate versus sodium chloride to prevent contrast-induced nephropathy in patients undergoing an emergent coronary procedure.
2007 Sep 1
G418-mediated ribosomal read-through of a nonsense mutation causing autosomal recessive proximal renal tubular acidosis.
2008 Sep
High sensitivity of RBL-2H3 cells to cadmium and manganese: an implication of the role of ZIP8.
2011 Jul
Evaluation of aggregating brain cell cultures for the detection of acute organ-specific toxicity.
2013 Jun
Magnetic resonance spectroscopy of the ischemic brain under lithium treatment. Link to mitochondrial disorders under stroke.
2015 Jul 25
Patents

Sample Use Guides

Optimal patient response to Lithium Carbonate usually can be established and maintained with 600 mg t.i.d. Optimal patient response to Lithium Oral Solution usually can be established and maintained with 10 mL (2 full teaspoons) (16 mEq of lithium) t.i.d. Such doses will normally produce an effective serum lithium level ranging between 1.0 and 1.5 mEq/l. Dosage must be individualized according to serum levels and clinical response. Regular monitoring of the patient’s clinical state and of serum lithium levels is necessary. Serum levels should be determined twice per week during the acute phase, and until the serum level and clinical condition of the patient have been stabilized.
Route of Administration: Oral
Although lithium at a high concentration (10 mM) activated β-catenin in different types of neurons, β-catenin shifted to the nucleus at a therapeutically relevant concentration (1 mM) only in thalamic neurons, both in vivo and in vitro.
Substance Class Chemical
Created
by admin
on Sat Jun 26 09:05:48 UTC 2021
Edited
by admin
on Sat Jun 26 09:05:48 UTC 2021
Record UNII
R9Z042Z19E
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LITHIUM BENZOATE
MART.   MI   WHO-DD  
Systematic Name English
LITHIUM BENZOICUM
HPUS  
Common Name English
LITHIUM BENZOATE [MI]
Common Name English
LITHIUM BENZOICUM [HPUS]
Common Name English
LITHIUM BENZOATE [MART.]
Common Name English
BENZOIC ACID, LITHIUM SALT
Common Name English
LITHIUM BENZOATE [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C448
Created by admin on Sat Jun 26 09:05:48 UTC 2021 , Edited by admin on Sat Jun 26 09:05:48 UTC 2021
Code System Code Type Description
MERCK INDEX
M6849
Created by admin on Sat Jun 26 09:05:48 UTC 2021 , Edited by admin on Sat Jun 26 09:05:48 UTC 2021
PRIMARY Merck Index
ECHA (EC/EINECS)
209-042-6
Created by admin on Sat Jun 26 09:05:48 UTC 2021 , Edited by admin on Sat Jun 26 09:05:48 UTC 2021
PRIMARY
CAS
553-54-8
Created by admin on Sat Jun 26 09:05:48 UTC 2021 , Edited by admin on Sat Jun 26 09:05:48 UTC 2021
PRIMARY
EVMPD
SUB14373MIG
Created by admin on Sat Jun 26 09:05:48 UTC 2021 , Edited by admin on Sat Jun 26 09:05:48 UTC 2021
PRIMARY
RXCUI
1363722
Created by admin on Sat Jun 26 09:05:48 UTC 2021 , Edited by admin on Sat Jun 26 09:05:48 UTC 2021
PRIMARY RxNorm
NCI_THESAURUS
C76050
Created by admin on Sat Jun 26 09:05:48 UTC 2021 , Edited by admin on Sat Jun 26 09:05:48 UTC 2021
PRIMARY
PUBCHEM
2724073
Created by admin on Sat Jun 26 09:05:48 UTC 2021 , Edited by admin on Sat Jun 26 09:05:48 UTC 2021
PRIMARY
EPA CompTox
553-54-8
Created by admin on Sat Jun 26 09:05:48 UTC 2021 , Edited by admin on Sat Jun 26 09:05:48 UTC 2021
PRIMARY
FDA UNII
R9Z042Z19E
Created by admin on Sat Jun 26 09:05:48 UTC 2021 , Edited by admin on Sat Jun 26 09:05:48 UTC 2021
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY